Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author WILLEGAIGNON, Jose FMUSP-HC
CREMA, Karin Paola FMUSP-HC
OLIVEIRA, Nathalie Canhameiro FMUSP-HC
PELISSONI, Rogerio Alexandre FMUSP-HC
COURA-FILHO, George Barberio FMUSP-HC
SAPIENZA, Marcelo Tatit FMUSP-HC
BUCHPIGUEL, Carlos Alberto FMUSP-HC
dc.date.issued 2018
dc.identifier.citation CLINICAL NUCLEAR MEDICINE, v.43, n.8, p.572-578, 2018
dc.identifier.issn 0363-9762
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/28083
dc.description.abstract Purpose I-131-metaiodobenzylguanidine (I-131-MIBG) has been used in the diagnosis and therapy of neuroblastoma in adult and pediatric patients for many years. In this study, we evaluated whole-body I-131-MIBG clearance and radiation doses received by patients, family caregivers, and medical staff to establish appropriate radiation safety measures to be used in therapy applications. Methods Research was focused on 23 children and adolescents with metastatic neuroblastoma, with ages ranging from 1.8 to 13 years, being treated with I-131-MIBG. Based on measured external dose rates from patients, dosimetric data to patients, family members, and others were calculated. Results The mean SD I-131-MIBG activity administered was 8.55 +/- 1.69 GBq. Percent whole-body retention rates of I-131-MIBG at 24, 48, and 72 hours after administration were 48% +/- 7%, 23% +/- 7%, and 12% +/- 6%, with a whole-body I-131-MIBG effective half-life of 23 +/- 5 hours for all patients. The mean doses for patients were 0.234 +/- 0.096 mGyMBq(-1) to red-marrow and 0.251 +/- 0.101 mGyMBq(-1) to whole body. The maximum potential radiation doses transmitted by patients to others at 1.0 m was estimated to be 11.9 +/- 3.4 mSv, with 97% of this dose occurring over 120 hours after therapy administration. Measured mean dose received by the 22 family caregivers was 1.88 +/- 1.85 mSv, and that received by the 19 pediatric physicians was 43 +/- 51 Sv. Conclusion In this study, we evaluated the whole-body clearance of I-131-MIBG in 23 pediatric patients, and the radiation doses received by family caregivers and medical staff during these therapy procedures, thus facilitating the establishment of radiation safety measures to be applied in pediatric therapy.
dc.language.iso eng
dc.publisher LIPPINCOTT WILLIAMS & WILKINS
dc.relation.ispartof Clinical Nuclear Medicine
dc.rights restrictedAccess
dc.subject neuroblastoma; I-131-MIBG; therapy; radiation exposure; dosimetry
dc.subject.other i-131 metaiodobenzylguanidine; neuroendocrine tumors; cancer-therapy; thyroid-cancer; i-131-metaiodobenzylguanidine; dosimetry; children; mibg; iodine-131-metaiodobenzylguanidine; exposure
dc.title Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures
dc.type article
dc.rights.holder Copyright LIPPINCOTT WILLIAMS & WILKINS
dc.description.group LIM/43
dc.identifier.doi 10.1097/RLU.0000000000002158
dc.identifier.pmid 29916922
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author WILLEGAIGNON, Jose:HC:ICESP
hcfmusp.author CREMA, Karin Paola:HC:INRAD
hcfmusp.author OLIVEIRA, Nathalie Canhameiro:HC:INRAD
hcfmusp.author PELISSONI, Rogerio Alexandre:HC:ICESP
hcfmusp.author COURA-FILHO, George Barberio:HC:ICESP
hcfmusp.author SAPIENZA, Marcelo Tatit:FM:MDR
hcfmusp.author BUCHPIGUEL, Carlos Alberto:FM:MDR
hcfmusp.origem.id WOS:000439523100014
hcfmusp.origem.id 2-s2.0-85050167058
hcfmusp.publisher.city PHILADELPHIA
hcfmusp.publisher.country USA
hcfmusp.relation.reference · BOLSTER AA, 1995, BRIT J RADIOL, V68, P481, DOI 10.1259/0007-1285-68-809-481
· Chu BP, 2016, PEDIATR BLOOD CANCER, V63, P801, DOI 10.1002/pbc.25892
· Cougnenc O, 2017, RADIAT PROT DOSIM, V173, P395, DOI 10.1093/rpd/ncw030
· FIELDING SL, 1991, EUR J NUCL MED, V18, P308, DOI 10.1007/BF02285457
· Gains JE, 2015, PEDIATR BLOOD CANCER, V62, P235, DOI 10.1002/pbc.25250
· Han S, 2017, CLIN NUCL MED, V42, P271, DOI 10.1097/RLU.0000000000001546
· Hjornevik T, 2015, J NUCL MED RAD THER, V6, P1
· HOEFNAGEL CA, 1987, J NUCL MED, V28, P308
· International Commission on Radiological Protection, 2004, ICRP PUBL, V94
· Markelewicz RJ, 2013, CLIN NUCL MED, V38, P604, DOI 10.1097/RLU.0b013e31829af3c8
· Matthay KK, 2006, J CLIN ONCOL, V24, P500, DOI 10.1200/JCO.2005.03.6400
· Minguez P, 2015, MED PHYS, V42, P3969, DOI 10.1118/1.4921807
· Monsieurs M, 2002, EUR J NUCL MED MOL I, V29, P1581, DOI 10.1007/s00259-002-0973-4
· Radiological Protection Institute of Ireland, 2009, 0901 RPII NUCL EN BO
· Shulkin BL, 1998, J NUCL MED, V39, P679
· Stabin MG, 2008, FUNDAMENTALS NUCL ME
· Trieu M, 2016, PEDIATR BLOOD CANCER, V63, P436, DOI 10.1002/pbc.25816
· Tristam M, 1996, J NUCL MED, V37, P1058
· Wafelman AR, 1997, EUR J NUCL MED, V24, P544
· Willegaignon J, 2006, HEALTH PHYS, V91, P119, DOI 10.1097/01.HP.0000202232.98823.87
· Willegaignon J, 2006, HEALTH PHYS, V91, P123, DOI 10.1097/01.HP.0000206041.25242.c0
· Willegaignon J, 2006, HEALTH PHYS, V91, P624, DOI 10.1097/01.HP.0000225467.10064.34
dc.description.index MEDLINE
dc.identifier.eissn 1536-0229
hcfmusp.citation.scopus 1
hcfmusp.citation.wos 2


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics